Ventyx Biosciences (VTYX) Stock Price, News & Analysis

Company Overview

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Key Stats

• Today's Range: $1.61 to $1.73
• 50-Day Range: $1.62 to $2.52
• 52-Week Range: $1.57 to $11.48
• Volume: 418,408 shs
• Average Volume: 1.62 million shs
• Market Capitalization: $114.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Ventyx Biosciences Stock Analysis - MarketRank™

Ventyx Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 386th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ventyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ventyx Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ventyx Biosciences is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ventyx Biosciences is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ventyx Biosciences has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.04% of the float of Ventyx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ventyx Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ventyx Biosciences has recently decreased by 4.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ventyx Biosciences does not currently pay a dividend.

Dividend Growth

Ventyx Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.04% of the float of Ventyx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ventyx Biosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ventyx Biosciences has recently decreased by 4.64%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.04

News Sentiment

Ventyx Biosciences has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for VTYX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Ventyx Biosciences insiders have bought 1,486.25% more of their company's stock than they have sold. Specifically, they have bought $1,262,415.00 in company stock and sold $79,585.00 in company stock.

Percentage Held by Insiders

18.18% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTYX Stock Analysis - Frequently Asked Questions

How have VTYX shares performed this year?

Ventyx Biosciences' stock was trading at $2.19 on January 1st, 2025. Since then, VTYX stock has decreased by 24.9% and is now trading at $1.6450.
View the best growth stocks for 2025 here.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12.

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Top institutional investors of Ventyx Biosciences include Bank of America Corp DE (6.04%), Vestal Point Capital LP (2.83%), Point72 Asset Management L.P. (2.52%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, John Nuss, Christopher W Krueger, Sheila Gujrathi, William J Sandborn and Martin Auster.
View institutional ownership trends.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ventyx Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTYX
• CUSIP: N/A
• CIK: 1851194
• Web: www.ventyxbio.com
• Phone: 760-593-4832
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +493.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-192,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.94%
• Return on Assets: -50.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.52
• Quick Ratio: 23.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.13 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 70,710,000
• Free Float: 57,856,000
• Market Cap: $119.15 million
• Optionable: Optionable
• Beta: 0.52